Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients

Mei Hsuan Lee; Chung Feng Huang; Hsueh Chou Lai; Chun Yen Lin; Chia Yen Dai; Chun Jen Liu; Jing Houng Wang; Jee Fu Huang; Wen Pang Su; Hung Chih Yang; Kwong Ming Kee; Ming Lun Yeh; Po Heng Chuang; Shih Jer Hsu; Ching I. Huang; Jung Ta Kao; Chieh Chang Chen; Sheng Hung Chen; Wen Juei Jeng; Hwai I. Yang; Yong Yuan; Sheng Nan Lu; I. Shyan Sheen; Chen Hua Liu; Cheng Yuan Peng; Jia Horng Kao; Ming Lung Yu; Wan Long Chuang; Chien Jen Chen

doi:10.1038/s41598-017-02313-y

Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients

Mei Hsuan Lee^*, Chung Feng Huang, Hsueh Chou Lai, Chun Yen Lin, Chia Yen Dai, Chun Jen Liu, Jing Houng Wang, Jee Fu Huang, Wen Pang Su, Hung Chih Yang, Kwong Ming Kee, Ming Lun Yeh, Po Heng Chuang, Shih Jer Hsu, Ching I. Huang, Jung Ta Kao, Chieh Chang Chen, Sheng Hung Chen, Wen Juei Jeng, Hwai I. YangYong Yuan, Sheng Nan Lu, I. Shyan Sheen, Chen Hua Liu, Cheng Yuan Peng, Jia Horng Kao, Ming Lung Yu, Wan Long Chuang, Chien Jen Chen

^*Corresponding author for this work

School of Medicine

Research output: Contribution to journal › Journal Article › peer-review

17 Scopus citations

Abstract

This follow-up study enrolled chronic hepatitis C patients to evaluate the treatment efficacy and to identify post-treatment seromarkers associated with risk of hepatocellular carcinoma (HCC) among patients with a sustained virological response (SVR) or nonsustained virological response (NSVR). A total of 4639 patients who received pegylated interferon and ribavirin during 2004-2013 were followed until December 2014. HCC was confirmed through health examinations and data linkage with a national database. A total of 233 HCC cases were reported after 26,163 person-years of follow-up, indicating an incidence of 8.9 per 1000 person-years: 6.9 for SVR and 21.6 for NSVR per 1000 person-years. The associated risk of HCC in patients with SVR was 0.37 (0.22-0.63) for those without cirrhosis and 0.54 (0.31-0.92) for those with cirrhosis compared with their respective counterparts with NSVR. Among patients with SVR, advanced age, male gender, cirrhosis, decreased platelet count, and increased aspartate aminotransferase and α-fetoprotein levels were associated with HCC (p < 0.001). The treatment of chronic hepatitis C patients before they developed cirrhosis showed a higher efficacy than did the treatment of those who had already developed cirrhosis. Patients with SVR may still have a risk of HCC and need to be regularly monitored.

Original language	English
Article number	3718
Journal	Scientific Reports
Volume	7
Issue number	1
DOIs	https://doi.org/10.1038/s41598-017-02313-y
State	Published - 01 12 2017

Bibliographical note

Publisher Copyright:
© 2017 The Author(s).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41598-017-02313-y

Cite this

Lee, M. H., Huang, C. F., Lai, H. C., Lin, C. Y., Dai, C. Y., Liu, C. J., Wang, J. H., Huang, J. F., Su, W. P., Yang, H. C., Kee, K. M., Yeh, M. L., Chuang, P. H., Hsu, S. J., Huang, C. I., Kao, J. T., Chen, C. C., Chen, S. H., Jeng, W. J., ... Chen, C. J. (2017). Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients. Scientific Reports, 7(1), Article 3718. https://doi.org/10.1038/s41598-017-02313-y

@article{cd5ea8ca5bd64996a3d98ede1320f838,

title = "Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients",

abstract = "This follow-up study enrolled chronic hepatitis C patients to evaluate the treatment efficacy and to identify post-treatment seromarkers associated with risk of hepatocellular carcinoma (HCC) among patients with a sustained virological response (SVR) or nonsustained virological response (NSVR). A total of 4639 patients who received pegylated interferon and ribavirin during 2004-2013 were followed until December 2014. HCC was confirmed through health examinations and data linkage with a national database. A total of 233 HCC cases were reported after 26,163 person-years of follow-up, indicating an incidence of 8.9 per 1000 person-years: 6.9 for SVR and 21.6 for NSVR per 1000 person-years. The associated risk of HCC in patients with SVR was 0.37 (0.22-0.63) for those without cirrhosis and 0.54 (0.31-0.92) for those with cirrhosis compared with their respective counterparts with NSVR. Among patients with SVR, advanced age, male gender, cirrhosis, decreased platelet count, and increased aspartate aminotransferase and α-fetoprotein levels were associated with HCC (p < 0.001). The treatment of chronic hepatitis C patients before they developed cirrhosis showed a higher efficacy than did the treatment of those who had already developed cirrhosis. Patients with SVR may still have a risk of HCC and need to be regularly monitored.",

author = "Lee, \{Mei Hsuan\} and Huang, \{Chung Feng\} and Lai, \{Hsueh Chou\} and Lin, \{Chun Yen\} and Dai, \{Chia Yen\} and Liu, \{Chun Jen\} and Wang, \{Jing Houng\} and Huang, \{Jee Fu\} and Su, \{Wen Pang\} and Yang, \{Hung Chih\} and Kee, \{Kwong Ming\} and Yeh, \{Ming Lun\} and Chuang, \{Po Heng\} and Hsu, \{Shih Jer\} and Huang, \{Ching I.\} and Kao, \{Jung Ta\} and Chen, \{Chieh Chang\} and Chen, \{Sheng Hung\} and Jeng, \{Wen Juei\} and Yang, \{Hwai I.\} and Yong Yuan and Lu, \{Sheng Nan\} and Sheen, \{I. Shyan\} and Liu, \{Chen Hua\} and Peng, \{Cheng Yuan\} and Kao, \{Jia Horng\} and Yu, \{Ming Lung\} and Chuang, \{Wan Long\} and Chen, \{Chien Jen\}",

note = "Publisher Copyright: {\textcopyright} 2017 The Author(s).",

year = "2017",

month = dec,

day = "1",

doi = "10.1038/s41598-017-02313-y",

language = "英语",

volume = "7",

journal = "Scientific Reports",

issn = "2045-2322",

publisher = "Nature Research",

number = "1",

}

Lee, MH, Huang, CF, Lai, HC, Lin, CY, Dai, CY, Liu, CJ, Wang, JH, Huang, JF, Su, WP, Yang, HC, Kee, KM, Yeh, ML, Chuang, PH, Hsu, SJ, Huang, CI, Kao, JT, Chen, CC, Chen, SH, Jeng, WJ, Yang, HI, Yuan, Y, Lu, SN, Sheen, IS, Liu, CH, Peng, CY, Kao, JH, Yu, ML, Chuang, WL & Chen, CJ 2017, 'Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients', Scientific Reports, vol. 7, no. 1, 3718. https://doi.org/10.1038/s41598-017-02313-y

TY - JOUR

T1 - Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients

AU - Lee, Mei Hsuan

AU - Huang, Chung Feng

AU - Lai, Hsueh Chou

AU - Lin, Chun Yen

AU - Dai, Chia Yen

AU - Liu, Chun Jen

AU - Wang, Jing Houng

AU - Huang, Jee Fu

AU - Su, Wen Pang

AU - Yang, Hung Chih

AU - Kee, Kwong Ming

AU - Yeh, Ming Lun

AU - Chuang, Po Heng

AU - Hsu, Shih Jer

AU - Huang, Ching I.

AU - Kao, Jung Ta

AU - Chen, Chieh Chang

AU - Chen, Sheng Hung

AU - Jeng, Wen Juei

AU - Yang, Hwai I.

AU - Yuan, Yong

AU - Lu, Sheng Nan

AU - Sheen, I. Shyan

AU - Liu, Chen Hua

AU - Peng, Cheng Yuan

AU - Kao, Jia Horng

AU - Yu, Ming Lung

AU - Chuang, Wan Long

AU - Chen, Chien Jen

PY - 2017/12/1

Y1 - 2017/12/1

N2 - This follow-up study enrolled chronic hepatitis C patients to evaluate the treatment efficacy and to identify post-treatment seromarkers associated with risk of hepatocellular carcinoma (HCC) among patients with a sustained virological response (SVR) or nonsustained virological response (NSVR). A total of 4639 patients who received pegylated interferon and ribavirin during 2004-2013 were followed until December 2014. HCC was confirmed through health examinations and data linkage with a national database. A total of 233 HCC cases were reported after 26,163 person-years of follow-up, indicating an incidence of 8.9 per 1000 person-years: 6.9 for SVR and 21.6 for NSVR per 1000 person-years. The associated risk of HCC in patients with SVR was 0.37 (0.22-0.63) for those without cirrhosis and 0.54 (0.31-0.92) for those with cirrhosis compared with their respective counterparts with NSVR. Among patients with SVR, advanced age, male gender, cirrhosis, decreased platelet count, and increased aspartate aminotransferase and α-fetoprotein levels were associated with HCC (p < 0.001). The treatment of chronic hepatitis C patients before they developed cirrhosis showed a higher efficacy than did the treatment of those who had already developed cirrhosis. Patients with SVR may still have a risk of HCC and need to be regularly monitored.

AB - This follow-up study enrolled chronic hepatitis C patients to evaluate the treatment efficacy and to identify post-treatment seromarkers associated with risk of hepatocellular carcinoma (HCC) among patients with a sustained virological response (SVR) or nonsustained virological response (NSVR). A total of 4639 patients who received pegylated interferon and ribavirin during 2004-2013 were followed until December 2014. HCC was confirmed through health examinations and data linkage with a national database. A total of 233 HCC cases were reported after 26,163 person-years of follow-up, indicating an incidence of 8.9 per 1000 person-years: 6.9 for SVR and 21.6 for NSVR per 1000 person-years. The associated risk of HCC in patients with SVR was 0.37 (0.22-0.63) for those without cirrhosis and 0.54 (0.31-0.92) for those with cirrhosis compared with their respective counterparts with NSVR. Among patients with SVR, advanced age, male gender, cirrhosis, decreased platelet count, and increased aspartate aminotransferase and α-fetoprotein levels were associated with HCC (p < 0.001). The treatment of chronic hepatitis C patients before they developed cirrhosis showed a higher efficacy than did the treatment of those who had already developed cirrhosis. Patients with SVR may still have a risk of HCC and need to be regularly monitored.

UR - https://www.scopus.com/pages/publications/85020937931

U2 - 10.1038/s41598-017-02313-y

DO - 10.1038/s41598-017-02313-y

M3 - 文章

C2 - 28623331

AN - SCOPUS:85020937931

SN - 2045-2322

VL - 7

JO - Scientific Reports

JF - Scientific Reports

IS - 1

M1 - 3718

ER -

Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this